Genomic sequencing has become a key tool in the investigation of foetal anomalies, with a growing shift from targeted panels to exome and genome sequencing. These broader approaches generate significantly more data, underscoring the need for robust bioinformatics pipelines. However, practices vary widely between laboratories. This systematic review explores current differences in bioinformatics workflows, the transparency of reporting, and the clinical impact of these variations. Using a search strategy from a previous review of prenatal sequencing studies (2018–2022), we identified 89 new records. Combined with 65 from the earlier review, a total of 154 articles were included. Data extraction focused on bioinformatics pipeline details across all analytical stages, with attention to clinical relevance. We found that reporting of bioinformatics methods was frequently incomplete. Tool names and versions were often omitted, quality control steps were poorly described, and filtering strategies lacked reproducibility. These deficiencies in reporting hinder readers from fully interpreting the sequencing results and understanding the potential limitations. To address this, we propose a checklist of essential bioinformatics metrics to improve reporting standards and support reproducible, clinically meaningful analyses.
Background: Establishing best practice recommendations helps to increase consistency, equity and innovation in clinical genomics services. Bioinformatics approaches are a core component of clinical genomics services that use high-throughput genomic sequencing applied in the diagnosis of rare disorders and cancer. While a broad range of international recommendations exist for genomic diagnostic testing and genetic variant classification, the current UK-specific best practice recommendations for bioinformatics approaches applied in this context are outdated. Methods: We assembled a team of bioinformaticians and scientists with diverse expertise in rare disease and cancer genomics applied in clinical diagnostics within the UK National Health Service. Through structured discussion, polls and surveys, we developed an updated set of best practice recommendations for bioinformatics approaches applied to high-throughput genomic sequencing in clinical genomic testing. Results: We provide best practice recommendations across the spectrum of activities within a clinical genomics bioinformatics pipeline, including quality control, primary, secondary and tertiary analysis approaches and shared knowledge bases. We also comment on issues related to software development and maintenance. The recommendations can be applied to multiple sequencing technologies and encompass both targeted and whole genome sequencing approaches applied to germline and tumour DNA samples. Conclusion: The best practice recommendations outlined in this study provide a national framework for adoption and innovation of bioinformatics approaches across diverse clinical genomic testing strategies in the UK National Health Service.